
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Shares of ATAI Life Sciences NV (NASDAQ:ATAI) fell sharply in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.